Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2018 Results - Earnings Call Transcript [Seeking Alpha]
Aldeyra Therapeutics, Inc. (ALDX)
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aldeyra.com/investor-relations
Company Research
Source: Seeking Alpha
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX ) Q2 2018 Earnings Conference Call August 9, 2018 8:00 AM ET Executives Joshua Reed - CFO Todd Brady - CEO, President & Director Analysts Neil Carnahan - Stifel, Nicolaus & Company Elemer Piros - Cantor Fitzgerald & Co. I-Eh Jen - Laidlaw & Company Corey Davis - Seaport Global Securities Operator Good day, and welcome to the Aldeyra Therapeutics Second Quarter 2018 Conference Call. [Operator Instructions]. Please note this event is being recorded. I would now like to turn the conference over to Joshua Reed, Chief Financial Officer. Please go ahead. Joshua Reed Good morning, everyone. I'm Joshua Reed, Chief Financial Officer of Aldeyra Therapeutics, and welcome to the Aldeyra Therapeutics conference call to discuss our second quarter 2018 financial results. With me today is Dr. Todd Brady, Chief Executive Officer of Aldeyra Therapeutics. Before we get started, we would like to remind you that this conferen
Show less
Read more
Impact Snapshot
Event Time:
ALDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALDX alerts
High impacting Aldeyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALDX
News
- Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease [Yahoo! Finance]Yahoo! Finance
- Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye DiseaseBusiness Wire
- Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Aldeyra Therapeutics, Inc (NASDAQ: ALDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Aldeyra Therapeutics, Inc (NASDAQ: ALDX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.MarketBeat
ALDX
Earnings
- 5/2/24 - Miss
ALDX
Sec Filings
- 5/2/24 - Form 10-Q
- 4/25/24 - Form 8-K
- 4/25/24 - Form EFFECT
- ALDX's page on the SEC website